On Friday, a memorandum signed by Marco Rubio called for a 90-day cessation of foreign aid. That would likely put on hold the ...

The UN Development Programme has recently delivered 3000 antiretroviral drugs to Fiji to support the HIV response. A report ...

At least 3000 women residents in Assiga Community, Yakurr local government area in Cross River State have been screened for ...

Another reason behind the fall in shares of Laurus today was the withdrawal of the US from the World Health Organization (WHO ...

Legacy’s trusted health care professionals are here to help patients living with HIV start and stay on treatment. Legacy ...

Goldman Sachs has retained its ‘Sell’ rating on Laurus Labs, setting a price target of ₹475. The brokerage noted that although the management did not offer specific revenue guidance for FY2025.

For the quarter that just concluded, Antiviral APIs formed 22% of Laurus Labs' overall topline, while Onco-APIs formed 12% of the topline, according to a report by Motilal Oswal.

Laurus Labs reported a 7% YoY drop in API revenues to Rs 531 crore for Q3 FY24, driven by lower ARV volumes. However, the FDF ...